NasdaqGS:RPRXPharmaceuticals
Royalty Pharma (RPRX) Stock Revenue Strength Masks Thin Earnings
Royalty Pharma stock barely budged after earnings, up just 0.5% to about US$57.75, yet the quarter itself was anything but flat. The market is treating this like a routine update, while the headline is a sharp squeeze in profitability. Net income excluding extra items came in at US$18 million on US$674 million of revenue, a fraction of recent quarters.
For a company that sells long duration royalty cash flows, that disconnect between a rich P/E, strong cash metrics and thin reported earnings...